BRPI0417744B8 - método para produzir um conjugado imunogênico, e,conjugado imunogênico - Google Patents

método para produzir um conjugado imunogênico, e,conjugado imunogênico

Info

Publication number
BRPI0417744B8
BRPI0417744B8 BRPI0417744A BRPI0417744A BRPI0417744B8 BR PI0417744 B8 BRPI0417744 B8 BR PI0417744B8 BR PI0417744 A BRPI0417744 A BR PI0417744A BR PI0417744 A BRPI0417744 A BR PI0417744A BR PI0417744 B8 BRPI0417744 B8 BR PI0417744B8
Authority
BR
Brazil
Prior art keywords
immunogenic
conjugate
producing
immunogenic conjugate
protein
Prior art date
Application number
BRPI0417744A
Other languages
English (en)
Inventor
Krishna Prasad A
G Arumugham Rasappa
Original Assignee
Wyeth Corp
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34700142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0417744(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Wyeth Llc filed Critical Wyeth Corp
Publication of BRPI0417744A publication Critical patent/BRPI0417744A/pt
Publication of BRPI0417744A8 publication Critical patent/BRPI0417744A8/pt
Publication of BRPI0417744B1 publication Critical patent/BRPI0417744B1/pt
Publication of BRPI0417744B8 publication Critical patent/BRPI0417744B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

método para produzir um conjugado imunogênico, e, conjugado imunogênico a presente invenção é dirigida a métodos de produzir conjugados de imunógenos de peptídeo com moléculas portadoras de proteína/polipeptídeo, que são úteis como imunógenos, em que os imunógenos de peptídeo são conjugados com portadores de proteína via grupos funcionais ativados de resíduos de aminoácido do portador ou da molécula ligadora opcionalmente fixada e em que quaisquer grupos funcionais reativos não-conjugados nos resíduos de aminoácido são inativados via capeamento, assim retendo a funcionalidade imunológica da molécula portadora, porém reduzindo a propensão para reações indesejáveis, que poderiam tornar o conjugado menos seguro ou eficaz. além disso, a invenção também refere-se a tais produtos imunogênicos e composições imunogênicas contendo tais produtos imunogênicos, produzidos por tais métodos.
BRPI0417744A 2003-12-17 2004-12-17 método para produzir um conjugado imunogênico, e,conjugado imunogênico BRPI0417744B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53048003P 2003-12-17 2003-12-17
US60/530480 2003-12-17
PCT/US2004/042701 WO2005058940A2 (en) 2003-12-17 2004-12-17 Immunogenic peptide carrier conjugates and methods of producing same

Publications (4)

Publication Number Publication Date
BRPI0417744A BRPI0417744A (pt) 2007-04-10
BRPI0417744A8 BRPI0417744A8 (pt) 2017-08-08
BRPI0417744B1 BRPI0417744B1 (pt) 2020-11-03
BRPI0417744B8 true BRPI0417744B8 (pt) 2021-05-25

Family

ID=34700142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417744A BRPI0417744B8 (pt) 2003-12-17 2004-12-17 método para produzir um conjugado imunogênico, e,conjugado imunogênico

Country Status (27)

Country Link
US (1) US20070134762A1 (pt)
EP (1) EP1701968B1 (pt)
JP (1) JP4764830B2 (pt)
KR (1) KR101157694B1 (pt)
CN (1) CN1984676A (pt)
AR (1) AR046960A1 (pt)
AU (1) AU2004299501B2 (pt)
BR (1) BRPI0417744B8 (pt)
CA (1) CA2549132C (pt)
CR (1) CR8444A (pt)
DK (1) DK1701968T3 (pt)
EA (2) EA010060B1 (pt)
EC (1) ECSP066655A (pt)
ES (1) ES2546175T3 (pt)
HU (1) HUE026000T2 (pt)
IL (1) IL176006A0 (pt)
MY (1) MY146566A (pt)
NO (1) NO340432B1 (pt)
NZ (1) NZ548352A (pt)
PL (1) PL1701968T3 (pt)
PT (1) PT1701968E (pt)
SG (2) SG182163A1 (pt)
SI (1) SI1701968T1 (pt)
TW (1) TWI355390B (pt)
UA (1) UA93854C2 (pt)
WO (1) WO2005058940A2 (pt)
ZA (1) ZA200604957B (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1699810A4 (en) * 2003-12-17 2009-10-21 Elan Pharm Inc A BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATE AND METHOD FOR THE PRODUCTION THEREOF
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
CA2582194A1 (en) * 2004-10-05 2006-04-20 Neuralab Limited Methods and compositions for improving recombinant protein production
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2006246382A1 (en) * 2005-05-05 2006-11-16 Merck Sharp & Dohme Corp. Peptide conjugate compositions and methods for the prevention and treatment of Alzheimer's disease
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
CN104857500A (zh) * 2005-11-02 2015-08-26 杜克大学 同时的化学疗法和免疫疗法
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
EP1996227A2 (en) * 2006-02-24 2008-12-03 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
WO2007112079A2 (en) * 2006-03-24 2007-10-04 Duke University Multivalent immunogen
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9675679B2 (en) * 2006-08-01 2017-06-13 The Scripps Research Institute Vaccines and methods for controlling adiposity
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2231180B1 (en) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
EP2145898A1 (en) 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SA114350400B1 (ar) 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
CN101671689B (zh) * 2009-07-29 2013-05-01 中国农业科学院上海兽医研究所 含日本血吸虫基因的重组表达载体及其应用
CA2768346A1 (en) * 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
CA2781049A1 (en) * 2009-11-16 2011-05-19 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Inc. (poly)-glycerolphosphate-based anti-gram positive bacterial vaccine
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US20130116423A1 (en) 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
WO2011137181A1 (en) 2010-04-27 2011-11-03 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for moraxella vaccine
WO2011149778A1 (en) 2010-05-26 2011-12-01 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for neisseria meningitis vaccine
WO2013054329A1 (en) * 2011-10-10 2013-04-18 Yeda Research And Development Co. Ltd. Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
JP2013538558A (ja) 2010-07-19 2013-10-17 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｔｌｒ媒介疾患を治療するためのｔｏｌｌ様受容体（ｔｌｒ）の膜貫通型ドメインに基づくペプチド
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
DK2646462T3 (en) 2010-11-29 2017-07-03 Akershus Univ METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY
CN102526724B (zh) * 2011-01-14 2015-07-22 四川大学 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途
WO2012158701A1 (en) * 2011-05-18 2012-11-22 Matrivax Research & Development Corporation Protein matrix vaccine compositions including polycations
KR101281098B1 (ko) * 2011-06-30 2013-07-02 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
CN102731659B (zh) * 2012-06-07 2014-05-07 北京交通大学 一种6×His-C99重组蛋白及其制备方法和应用
BR112014029403A2 (pt) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugados, anticorpo e formulação farmacêutica
CN103497927B (zh) * 2013-10-21 2016-02-10 深圳大学 表达分泌金葡菌肠毒素蛋白的重组bcg活菌菌株、活菌疫苗及其构建方法和应用
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SG11201610183XA (en) * 2014-05-07 2017-01-27 Applied Molecular Transp Llc Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN104059142B (zh) * 2014-07-03 2016-11-23 江南大学 一种用于制备沙门氏菌交叉型抗体的免疫原的合成方法
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN107406515B (zh) * 2014-12-18 2022-11-04 生物梅里埃公司 合成的双表位化合物
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN107648618B (zh) * 2017-09-27 2020-05-08 国家纳米科学中心 一种药物递送体系及其制备方法与应用
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN110018253A (zh) * 2019-04-15 2019-07-16 艾美卫信生物药业（浙江）有限公司 一种生物制品中游离蛋白含量的高效液相测定方法
CL2019003847A1 (es) * 2019-12-26 2021-08-06 Univ Pontificia Catolica Chile Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
US20230149534A1 (en) * 2020-03-20 2023-05-18 BioVaxys Inc. Haptenized coronavirus spike proteins
CN111499724A (zh) * 2020-04-15 2020-08-07 上海领潮生物新材料有限公司 一种s-腺苷同型半胱氨酸-鸡卵白蛋白偶联物的制备方法
WO2021226849A1 (zh) * 2020-05-12 2021-11-18 中国科学院过程工程研究所 一类免疫活性肽-胆绿素的缀合物、其制备方法及应用
CN111896737B (zh) * 2020-08-03 2023-07-07 北京望尔生物技术有限公司 一种蛇形菌素人工抗原在酶联免疫试剂盒中的应用
JP2024504512A (ja) 2020-12-21 2024-01-31 コーネル・ユニバーシティー ペプチド連結薬物送達系
CA3221075A1 (en) * 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20260041748A1 (en) * 2022-07-29 2026-02-12 Lg Chem, Ltd. Recombinant fusion protein for antigen delivery and uses thereof
CN115583992B (zh) * 2022-11-02 2026-02-17 江南大学 一种氧化还原响应的载体蛋白及其在制备疫苗中的应用
CN116059401B (zh) * 2023-02-22 2025-04-29 东南大学 一种双功能纳米探针及其制备方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5245015A (en) * 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5192540A (en) 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK0600866T3 (da) 1990-06-01 1998-03-09 Chiron Corp Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
DK0604552T3 (da) 1991-09-18 1997-08-04 Affymax Tech Nv Fremgangsmåde til syntese af forskellige samlinger af oligomerer
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
AU685047B2 (en) * 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
EP0665897B1 (en) 1992-10-01 2003-07-09 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
BR9407947A (pt) 1993-11-02 1996-11-26 Affymax Tech Nv Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL115933A0 (en) 1995-11-09 1996-01-31 Oramir Semiconductor Ltd Process and apparatus for oblique beam revolution for the effective laser stripping of sidewalls
EP1281718A3 (en) 1995-11-10 2005-01-19 ELAN CORPORATION, Plc Peptides which enhance transport across tissues
CN1257976C (zh) 1996-10-23 2006-05-31 宾夕法尼亚州立大学托管会 改良疫苗
US6962984B2 (en) * 1996-12-05 2005-11-08 Nihon University IgA nephropathy-related DNA
EP0848011B1 (en) 1996-12-16 2001-03-21 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Method of coupling polysaccharides to proteins
US5877220A (en) * 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2792479A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
US6645503B1 (en) * 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
CA2264970A1 (en) * 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
US6945135B1 (en) * 1999-09-09 2005-09-20 L. H. Thomson Company, Inc. Bicycle stem for enlarged handlebar portions and associated methods
US20030190322A1 (en) * 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
US20030135035A1 (en) * 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
CA2466841A1 (en) * 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
WO2004080490A2 (en) * 2003-03-07 2004-09-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
EP1699810A4 (en) * 2003-12-17 2009-10-21 Elan Pharm Inc A BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATE AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
JP4764830B2 (ja) 2011-09-07
NO20062687L (no) 2006-09-15
EP1701968A4 (en) 2007-10-03
EA200601169A1 (ru) 2007-04-27
HK1091219A1 (en) 2007-01-12
KR101157694B1 (ko) 2012-06-20
EP1701968A2 (en) 2006-09-20
HUE026000T2 (en) 2016-04-28
SI1701968T1 (sl) 2015-08-31
TW200533681A (en) 2005-10-16
CA2549132A1 (en) 2005-06-30
NZ548352A (en) 2009-09-25
DK1701968T3 (da) 2015-06-22
BRPI0417744A (pt) 2007-04-10
AR046960A1 (es) 2006-01-04
EA010060B1 (ru) 2008-06-30
IL176006A0 (en) 2006-10-05
CR8444A (es) 2008-02-20
WO2005058940A3 (en) 2006-10-26
CA2549132C (en) 2017-03-07
ZA200604957B (en) 2008-01-08
PL1701968T3 (pl) 2015-11-30
KR20070027502A (ko) 2007-03-09
AU2004299501A1 (en) 2005-06-30
AU2004299501B2 (en) 2010-12-23
WO2005058940A2 (en) 2005-06-30
BRPI0417744B1 (pt) 2020-11-03
CN1984676A (zh) 2007-06-20
ECSP066655A (es) 2006-12-20
UA93854C2 (ru) 2011-03-25
JP2008505052A (ja) 2008-02-21
SG182163A1 (en) 2012-07-30
PT1701968E (pt) 2015-09-11
ES2546175T3 (es) 2015-09-21
NO340432B1 (no) 2017-04-24
MY146566A (en) 2012-08-30
BRPI0417744A8 (pt) 2017-08-08
EA012984B1 (ru) 2010-02-26
US20070134762A1 (en) 2007-06-14
TWI355390B (en) 2012-01-01
EA200800300A1 (ru) 2008-10-30
SG149013A1 (en) 2009-01-29
EP1701968B1 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
BRPI0417744A8 (pt) Método para produzir um conjugado imunogênico, e,conjugado imunogênico
BRPI0417689A8 (pt) Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado
BRPI0612654B8 (pt) método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína
Gauthier et al. Arginine-specific modification of proteins with polyethylene glycol
PE20091388A1 (es) Moleculas y metodos para modular el componente de complemento
Jbara et al. Oligonucleotide bioconjugation with bifunctional palladium reagents
BR0111191A (pt) Moléculas mutantes de ctla4 solúveis e seus usos
NZ726386A (en) Preparation of antibody maytansinoid conjugates
BRPI0417341A (pt) fator ix glicopeguilado
NO323870B1 (no) Fremgangsmate for a konjugere et peptid til et polysakkarid.
BR112022002309A2 (pt) Conjugado e usos do mesmo
Tyler et al. Single‐entity heparan sulfate glycomimetic clusters for therapeutic applications
WO2014057436A3 (en) Anticancer conjugate
EP0467700A2 (en) Coconjugate vaccines comprising immunogenic protein, HIV related peptides, and anionic moieties
CA2047031A1 (en) Peptide-polysaccharide-protein conjugate vaccines
BR0113439A (pt) Processo para a manufatura de um imunógeno para vacina, derivado de maleimida de peptìdeo de ige, uso do mesmo, conjugado adequado para uso em uma vacina e composição de vacina
Eilstein et al. Sensitization to p-amino aromatic compounds: study of the covalent binding of 2, 5-dimethyl-p-benzoquinonediimine to a model peptide by electrospray ionization tandem mass spectrometry
TH115317A (th) Ab อิมมูโนจีนิกเพปไทด์แคริเออร์คอนจูเกตและวิธีการผลิตสารเดียวกันนี้
Kragol et al. Synthesis of a disulfide-linked octameric peptide construct carrying three different antigenic determinants
EP4129344A1 (en) Immune inducer containing polynucleotide-peptide conjugate and pharmaceutical composition containing same
CN121175323A (zh) 复合物、药物组合物、疫苗及其应用
Taniguchi et al. 2P-025 Direct observation of GroEL-substrate complexes by high-speed atomic force microscopy (Protein: Structure & Function, The 47th Annual Meeting of the Biophysical Society of Japan)
HK40083994A (en) Immune inducer containing polynucleotide-peptide conjugate and pharmaceutical composition containing same
Nicola et al. A novel glycoconjugation method and unexpected photo-induced site-selective protein cleavage reaction
Kaita et al. 2P-026 Transduction of fluctuations along internal mechanical network in molecular machines (Protein: Structure & Function, The 47th Annual Meeting of the Biophysical Society of Japan)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: WYETH LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: WYETH LLC (US)

B25D Requested change of name of applicant approved

Owner name: WYETH LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.